Discovery and Development of Novel Ret Inhibitors for the Treatment of Pervasive Malignancies

Targeted cancer therapeutics represent the advent of a new therapeutic age, brought forth by the small molecule tyrosine kinase inhibitor (TKI) imatinib (Gleevec®). Imatinib is able to cause complete and sustained remissions in patients with chronic myelogenous leukemia (CML) driven by the Abelson...

Full description

Bibliographic Details
Main Author: Frett, Brendan
Other Authors: Li, Hong-yu
Language:en_US
Published: The University of Arizona. 2014
Subjects:
Online Access:http://hdl.handle.net/10150/325495

Similar Items